Emerging Therapies Plaque Psoriasis

>

Latest News

FDA Approves Adalimumab-aacf for Plaque Psoriasis, Hidradenitis Suppurativa and Other Conditions
FDA Approves Adalimumab-aacf for Plaque Psoriasis, Hidradenitis Suppurativa and Other Conditions

December 15th 2022

A biologic from Germany offers a new treatment option for a number of dermatologic conditions.

Consistent Efficacy With a Durable Safety Profile Through 5 Years and a Growing Body of Real-World Evidence
Consistent Efficacy With a Durable Safety Profile Through 5 Years and a Growing Body of Real-World Evidence

October 22nd 2022

Dermavant Announces Phase 3 PSOARING 3 Tapinarof Cream Data at AAD 2022
Dermavant Announces Phase 3 PSOARING 3 Tapinarof Cream Data at AAD 2022

March 25th 2022

Phase 3 Tapinarof Data Released
Phase 3 Tapinarof Data Released

December 8th 2021

 Psoriasis
C-Jun Protein Linked to Psoriasis

June 22nd 2021

© 2024 MJH Life Sciences

All rights reserved.